Granules India Limited Stock Price Today (NSE: GRANULES)
Fundamental Score
Granules India Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Granules India Limited share price today is ₹835.60, down 4.24% on NSE/BSE as of 16 September 2026. Granules India Limited (GRANULES) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹20.71K (Cr). The 52-week high for GRANULES share price is ₹923.65 and the 52-week low is ₹510.55. At a P/E ratio of 30.88x, GRANULES is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.52% and a debt-to-equity ratio of 0.26.
Granules India Limited Share Price Chart — NSE/BSE Historical Performance
Granules India Limited share price chart: 4.70% return over the past month. 52-week high ₹923.65, 52-week low ₹510.55.
Granules India Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹869.00 | ₹872.00 | ₹829.00 | ₹835.60 | 26.52L (Cr) | |
| ₹917.00 | ₹923.65 | ₹872.50 | ₹872.60 | 21.06L (Cr) | |
| ₹895.95 | ₹914.85 | ₹881.25 | ₹909.30 | 78.51L (Cr) | |
| ₹870.10 | ₹905.85 | ₹870.10 | ₹899.25 | 15.97L (Cr) | |
| ₹899.75 | ₹901.80 | ₹878.10 | ₹884.80 | 14.06L (Cr) | |
| ₹869.00 | ₹899.85 | ₹865.00 | ₹895.35 | 21.12L (Cr) | |
| ₹844.50 | ₹873.85 | ₹842.20 | ₹867.30 | 10.33L (Cr) | |
| ₹853.00 | ₹863.60 | ₹838.60 | ₹848.30 | 11.73L (Cr) | |
| ₹837.50 | ₹873.50 | ₹834.00 | ₹853.85 | 28.29L (Cr) | |
| ₹834.05 | ₹838.00 | ₹816.00 | ₹831.75 | 7.88L (Cr) |
Granules India Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹828.50 | ₹923.65 | ₹816.00 | ₹835.60 | +0.86% | |
| ₹827.80 | ₹883.00 | ₹814.20 | ₹828.50 | +0.08% | |
| ₹817.65 | ₹910.00 | ₹804.50 | ₹824.65 | +0.86% | |
| ₹780.00 | ₹817.70 | ₹736.50 | ₹813.25 | +4.26% | |
| ₹699.70 | ₹804.30 | ₹690.05 | ₹773.85 | +10.60% | |
| ₹629.00 | ₹730.80 | ₹602.20 | ₹699.70 | +11.24% | |
| ₹569.00 | ₹640.00 | ₹547.40 | ₹620.40 | +9.03% | |
| ₹552.90 | ₹606.95 | ₹537.65 | ₹582.25 | +5.31% | |
| ₹600.40 | ₹627.00 | ₹531.80 | ₹570.60 | -4.96% | |
| ₹562.50 | ₹624.70 | ₹540.55 | ₹598.50 | +6.40% | |
| ₹565.95 | ₹578.05 | ₹529.85 | ₹556.10 | -1.74% | |
| ₹522.70 | ₹587.20 | ₹522.70 | ₹565.60 | +8.21% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Granules India Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Granules India Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GRANULES across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (18.21%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (20.41%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (63.03%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (22.04%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.26)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.86x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.56)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹851.17 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 33.61%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
High Price-to-Book Ratio (5.45x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (2.10% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (1.61% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Granules India Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Granules India Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Granules India LimitedGranules India ...Selected✓ GRANULES • 532482 | 47.4/100 | ₹835.60₹836 | ₹20706.17₹20706.17 | 30.88Average 30.9 Average | 13.52%Average 13.52% Average | 18.21%Good 18.21% Good | 0.26Excellent 0.3 Excellent | 1.61%Average 1.61% Average | 10.63%Good 10.63% Good | 0.19% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Granules India Limited PE Ratio History
Historical price-to-earnings ratio for GRANULES — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹16.72 | ₹592.30 | 35.4x |
| FY 2023 | ₹21.00 | ₹405.45 | 19.3x |
| FY 2022 | ₹16.60 | ₹318.80 | 19.2x |
| FY 2021 | ₹21.95 | ₹336.20 | 15.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Granules India Limited Dividend History
Annual cash dividends paid by GRANULES — dividend yield 0.19%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹36.35 Cr |
| FY 2024 | ₹36.31 Cr |
| FY 2023 | ₹18.62 Cr |
| FY 2022 | ₹37.17 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Granules India Limited Quarterly Performance
Latest quarterly metrics for GRANULES — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
22.04%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
63.03%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.63%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
1.61%
Compounded annual net profit growth over 5 years
Granules India Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GRANULES — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Granules India Limited Financial Statements
Annual income statement, balance sheet and cash flow for Granules India Limited (GRANULES) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Granules India Limited
About GRANULES (Granules India Limited)
Granules India Ltd is a vertically integrated pharmaceutical company headquartered in Hyderabad, India, with a global footprint. It operates across the entire pharmaceutical value ...chain, from active pharmaceutical ingredients (APIs) to finished dosages (FDs), ensuring quality control and supply chain reliability. Granules specializes in manufacturing a diverse portfolio of essential medications, covering pain management, diabetes treatment, cough and cold remedies, and muscle relaxants. The company is renowned for its commitment to innovation, constantly striving to develop novel drug delivery systems and improve existing formulations. With a focus on sustainability and ethical business practices, Granules India Ltd is dedicated to providing affordable and accessible healthcare solutions to patients worldwide. Granules distinguishes itself through its robust manufacturing capabilities and state-of-the-art facilities, enabling the production of high-quality pharmaceutical products at scale. The company's strengths lie in its process chemistry expertise and efficient manufacturing processes, leading to cost competitiveness and timely delivery. Granules is a significant player in both the Indian and international markets, exporting its products to numerous countries across North America, Europe, Latin America, and Asia. Furthermore, the company emphasizes strategic collaborations and partnerships to expand its market reach and product offerings, solidifying its position as a trusted pharmaceutical supplier. This commitment to quality, affordability, and global reach makes Granules a vital contributor to the healthcare landscape. Granules also invests heavily in research and development, consistently seeking to improve its product portfolio and cater to unmet medical needs. Its R&D efforts focus on developing innovative formulations, improving drug efficacy, and reducing side effects. The company maintains a strong regulatory compliance record, adhering to the highest international standards and guidelines. Through its commitment to continuous improvement and innovation, Granules seeks to remain at the forefront of the pharmaceutical industry and contribute to improved patient outcomes globally. With a focus on affordability, innovation, and quality, Granules India Ltd stands as a reliable partner for healthcare providers and patients.
Company Details
Key Leadership
GRANULES Share Price: Frequently Asked Questions
What is the current share price of Granules India Limited?
Granules India Limited (GRANULES) trades at ₹835.60 on NSE and BSE. Market cap ₹20.71K (Cr). Educational data only.
What is the P/E ratio of Granules India Limited?
Granules India Limited has a P/E of 30.88x vs industry average 34.89x.
What is the Bull Run score for Granules India Limited?
Granules India Limited has a Bull Run score of 47.4/100 based on 25+ financial parameters.
Does Granules India Limited pay dividends?
Granules India Limited has a dividend yield of 0.19%. Past dividends don't guarantee future payments.
What is the ROE of Granules India Limited?
Granules India Limited has ROE of 13.52%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Granules India Limited?
Granules India Limited has debt-to-equity of 0.26.
Is Granules India Limited a good investment?
Bull Run gives Granules India Limited a score of 47.4/100. This is not investment advice — consult a SEBI-registered advisor.